Loading...
•
Mar 31, 2024
OrthoPediatrics Q1 2024 Earnings Report
OrthoPediatrics reported a strong first quarter, exceeding expectations with healthy revenue growth and strategic advancements.
Key Takeaways
OrthoPediatrics Corp. reported a 41% increase in revenue for Q1 2024, reaching $44.7 million, driven by growth in Trauma & Deformity and Scoliosis products, as well as the acquisition of Boston O&P. The company increased its full-year revenue guidance to $200.0 million to $203.0 million.
Revenue increased by 41% year-over-year, reaching $44.7 million.
U.S. revenue increased by 44%, while international revenue increased by 33%.
Trauma & Deformity revenue grew by 42%, and Scoliosis revenue grew by 44%.
Full year 2024 revenue guidance increased to $200.0 million - $203.0 million.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
The company increased its revenue guidance for the full year 2024 to $200.0 million - $203.0 million, representing growth of 34% to 36% over 2023 revenue. They reiterated annual set deployment to be less than $20.0 million and reiterated $8.0 million to $9.0 million of adjusted EBITDA for the full year of 2024.
Positive Outlook
- Increased full year 2024 revenue guidance to $200.0 million - $203.0 million, representing growth of 34% to 36% compared to prior year
- Annual set deployment to be less than $20.0 million.
- Adjusted EBITDA of $8.0 million to $9.0 million for the full year of 2024.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...